Literature DB >> 21190521

Role of mTOR signaling in tumor cell motility, invasion and metastasis.

Hongyu Zhou1, Shile Huang.   

Abstract

Tumor cell migration and invasion play fundamental roles in cancer metastasis. The mammalian target of rapamycin (mTOR), a highly conserved and ubiquitously expressed serine/threonine (Ser/Thr) kinase, is a central regulator of cell growth, proliferation, differentiation and survival. Recent studies have shown that mTOR also plays a critical role in the regulation of tumor cell motility, invasion and cancer metastasis. Current knowledge indicates that mTOR functions as two distinct complexes, mTORC1 and mTORC2. mTORC1 phosphorylates p70 S6 kinase (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), and regulates cell growth, proliferation, survival and motility. mTORC2 phosphorylates Akt, protein kinase C α (PKCα) and the focal adhesion proteins, and controls the activities of the small GTPases (RhoA, Cdc42 and Rac1), and regulates cell survival and the actin cytoskeleton. Here we briefly review recent knowledge of mTOR complexes and the role of mTOR signaling in tumor cell migration and invasion. We also discuss recent efforts about the mechanism by which rapamycin, a specific inhibitor of mTOR, inhibits cell migration, invasion and cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21190521      PMCID: PMC3410744          DOI: 10.2174/138920311795659407

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  179 in total

1.  Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a).

Authors:  A Brunet; J Park; H Tran; L S Hu; B A Hemmings; M E Greenberg
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.

Authors:  J Heitman; N R Movva; M N Hall
Journal:  Science       Date:  1991-08-23       Impact factor: 47.728

3.  Rho proteins induce metastatic properties in vivo.

Authors:  L del Peso; R Hernández-Alcoceba; N Embade; A Carnero; P Esteve; C Paje; J C Lacal
Journal:  Oncogene       Date:  1997-12-18       Impact factor: 9.867

4.  Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP.

Authors:  J Choi; J Chen; S L Schreiber; J Clardy
Journal:  Science       Date:  1996-07-12       Impact factor: 47.728

5.  Tumour-derived fibroblast growth factor-2 exerts lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells.

Authors:  Mitsuhiro Matsuo; Sanae Yamada; Keiichi Koizumi; Hiroaki Sakurai; Ikuo Saiki
Journal:  Eur J Cancer       Date:  2007-06-13       Impact factor: 9.162

Review 6.  Immunoregulatory functions of mTOR inhibition.

Authors:  Angus W Thomson; Hēth R Turnquist; Giorgio Raimondi
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

Review 7.  Tor signalling in bugs, brain and brawn.

Authors:  Estela Jacinto; Michael N Hall
Journal:  Nat Rev Mol Cell Biol       Date:  2003-02       Impact factor: 94.444

8.  ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons.

Authors:  S Tsukita; K Oishi; N Sato; J Sagara; A Kawai; S Tsukita
Journal:  J Cell Biol       Date:  1994-07       Impact factor: 10.539

9.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).

Authors:  Juan M García-Martínez; Jennifer Moran; Rosemary G Clarke; Alex Gray; Sabina C Cosulich; Christine M Chresta; Dario R Alessi
Journal:  Biochem J       Date:  2009-06-12       Impact factor: 3.857

10.  Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway.

Authors:  Samy Lamouille; Rik Derynck
Journal:  J Cell Biol       Date:  2007-07-23       Impact factor: 10.539

View more
  104 in total

Review 1.  Cancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasion.

Authors:  M Cecilia Caino; Dario C Altieri
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 2.  mTOR in health and in sickness.

Authors:  Dritan Liko; Michael N Hall
Journal:  J Mol Med (Berl)       Date:  2015-09-22       Impact factor: 4.599

Review 3.  Mitochondrial dynamics as regulators of cancer biology.

Authors:  Andrew Paul Trotta; Jerry Edward Chipuk
Journal:  Cell Mol Life Sci       Date:  2017-01-12       Impact factor: 9.261

Review 4.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

5.  Sustained PKCβII activity confers oncogenic properties in a phospholipase D- and mTOR-dependent manner.

Authors:  Mohamad El Osta; Mengling Liu; Mohamad Adada; Can E Senkal; Jolanta Idkowiak-Baldys; Lina M Obeid; Christopher J Clarke; Yusuf A Hannun
Journal:  FASEB J       Date:  2013-10-11       Impact factor: 5.191

Review 6.  Underlying Mechanisms for Distant Metastasis - Molecular Biology.

Authors:  Eva Pachmayr; Christoph Treese; Ulrike Stein
Journal:  Visc Med       Date:  2017-02-09

Review 7.  Molecular evidence of cryptotanshinone for treatment and prevention of human cancer.

Authors:  Wenxing Chen; Yin Lu; Guangying Chen; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2013-09       Impact factor: 2.505

8.  Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.

Authors:  Sang-Oh Yoon; Sejeong Shin; Florian A Karreth; Gwen R Buel; Mark P Jedrychowski; David R Plas; Shoukat Dedhar; Steven P Gygi; Philippe P Roux; Noah Dephoure; John Blenis
Journal:  Mol Cell       Date:  2017-07-27       Impact factor: 17.970

Review 9.  Repositioning the Old Fungicide Ciclopirox for New Medical Uses.

Authors:  Tao Shen; Shile Huang
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

10.  Knockdown of TOR signaling pathway regulator suppresses cell migration and invasion in non-small cell lung cancer via the regulation of epithelial-to-mesenchymal transition.

Authors:  Xiang Xu; Huangkai Zhu; Minglei Yang; Enkuo Zheng; Yinjie Zhou; Junjun Ni; Rui Li; Zhenhua Yang; Ti He; Guofang Zhao
Journal:  Exp Ther Med       Date:  2019-12-20       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.